WINT — Windtree Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study
Brief: Kraken And Windtree Therapeutics Announce Strategic Partnership For BNB Custody, Trading, And OTC Services
Brief: Windtree Therapeutics Enters Note Purchase Agreements On June 27, 2025
Brief: Windtree Announces Issuance Of Istaroxime Patent For The United States For Acute Heart Failure
Brief: Windtree Therapeutics Inc - Interim Analysis To Assess Safety, Tolerability, And Preliminary Efficacy
Brief: Windtree Advances Lower Cost Manufacturing Of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel
Brief: Windtree Announces Transformational Agreement To Acquire Revenue Generating Environmental Services Business
Brief: Windtree Therapeutics Inc - To Create Cryptocurrency Policy For Payments And Assets
Brief: Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Brief: Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics
Brief: Windtree Therapeutics Inc - On March 20, Entered License And Supply Agreement With Evofem Biosciences - SEC Filing
Windtree Therapeutics rises on licensing deal for birth control vaginal gel
Brief: Windtree Therapeutics Announces New Corporate Strategy
Brief: Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction
Windtree Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Windtree slides on CEO retirement